Sulfamato hydroxamic acid metalloprotease inhibitor

Details Sulfamato hydroxamic acid metalloprotease inhibitor Sulfamato hydroxamic acid metalloprotease inhibitor

2006-06-27

2006-06-27

Aulakh, Charanjit S. (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C546S187000, C514S316000, C514S269000, C514S256000, C544S323000, C544S335000

Reexamination Certificate

active

07067670

ABSTRACT:
A sulfamato hydroxamic acid compound that inter alia inhibits matrix metalloprotease activity is disclosed as are a process for preparing the same, intermediate compounds useful in those syntheses, and a treatment process that comprises administering a contemplated sulfamato hydroxamic acid compound in a MMP enzyme-inhibiting effective amount to a host having a condition associated with pathological matrix metalloprotease activity.

REFERENCES:
patent: 4595700 (1986-06-01), Donald et al.
patent: 5451676 (1995-09-01), Whittaker et al.
patent: 5472978 (1995-12-01), Baker et al.
patent: 5475138 (1995-12-01), Pal et al.
patent: 5599994 (1997-02-01), Pal et al.
patent: 5932595 (1999-08-01), Bender et al.
patent: 5998412 (1999-12-01), Broka et al.
patent: 6013649 (2000-01-01), Freskos et al.
patent: 6372758 (2002-04-01), DeCrescenzo et al.
patent: 6800646 (2004-10-01), DeCrescenzo et al.
patent: 2005/0009838 (2005-01-01), Barta et al.
patent: 0 266 182 (1988-05-01), None
patent: 0 336 354 (1994-02-01), None
patent: 0 606 046 (1994-07-01), None
patent: 0 780 386 (1997-06-01), None
patent: 0 930 067 (1999-07-01), None
patent: 0 931 788 (1999-07-01), None
patent: 0 994 104 (2000-04-01), None
patent: 1 081 137 (2001-03-01), None
patent: 1067965 (1967-05-01), None
patent: 2263109 (1993-07-01), None
patent: 4-338331 (1992-11-01), None
patent: WO 90/05719 (1990-05-01), None
patent: WO 93/20047 (1993-10-01), None
patent: WO 94/02466 (1994-02-01), None
patent: WO 94/24140 (1994-10-01), None
patent: WO 95/04720 (1995-02-01), None
patent: WO 95/09841 (1995-04-01), None
patent: WO 95/13064 (1995-05-01), None
patent: WO 95/13289 (1995-05-01), None
patent: WO 95/29892 (1995-11-01), None
patent: WO 96/06074 (1996-02-01), None
patent: WO 96/11209 (1996-04-01), None
patent: WO 97/05865 (1997-02-01), None
patent: WO 97/20824 (1997-06-01), None
patent: WO 97/24117 (1997-07-01), None
patent: WO 97/48368 (1997-12-01), None
patent: WO 98/37877 (1998-09-01), None
patent: WO 98/38163 (1998-09-01), None
patent: WO 98/38859 (1998-09-01), None
patent: WO 98/39329 (1998-09-01), None
patent: WO 99/09000 (1999-02-01), None
patent: WO 99/24399 (1999-05-01), None
patent: WO 99/25687 (1999-05-01), None
patent: WO 99/29667 (1999-06-01), None
patent: WO 99/42436 (1999-08-01), None
patent: WO 00/38717 (2000-06-01), None
patent: WO 00/46221 (2000-08-01), None
patent: WO 00/50396 (2000-08-01), None
patent: WO 00/59874 (2000-10-01), None
patent: WO 00/69819 (2000-11-01), None
patent: WO 00/69821 (2000-11-01), None
Pending claims from U.S. Appl. No. 10/700,202, filed Nov. 3, 2003, McDonald et al.
Dack et al.,Preparation of N-hydroxytetrahydropyridylsulfonylacetamides and related compounds as matrix metalloprotease inhibitors, CA 131:44740 (1999) [CA Plus Accession No. 1999:388166].
Denis et al.,Matrix metalloproteinase inhibitors: Present achievements and future prospects, Invest. New Drugs, 15:175-185 (1997).
Gearing et al.,Processing of tumour necrosis factor-α precursor by metalloproteinases, Nature, 370:555-557 (1994).
Search Report, Written Opinion, and Preliminary Examination Report for International Application No. PCT/US00/03061.
Kenyon et al.,A model of angiogenesis in the mouse cornea, Invest. Ophthalmol. Vis. Sci., 37(8):1625-1632 (1996).
Knight et al.,A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases, FEBS Lett. 296(3):263-266 (1992).
Luckow et al.,Efficient generation of infectious recombinant baculoviruses by site-specific transposon-mediated insertion of foreign genes into a baculovirus genome propagated in escherihia coli, J. Virol. 67:4566-4579 (1993).
McClure et al.,Matrix metalloprotease(MMP) -13 selective inhibitors for treatment of arthritis deformans and other MMP-related diseases, CA 131:125454 (1999) [CA Plus Accession No. 1999:468334].
McGeehan et al.,Regulation of tumour necrosis factor-α processing by a metalloproteinase inhibitor; Nature, 370:558-561 (1994).
Mitchell et al.,Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage, J. Clin. Invest., 97(3):761-768 (1996).
Rasmussen et al.,Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat, Pharmacol. Ther., 75(1):69-75 (1997).
Reboul et al.,The new collagenase, collagnease-3, is expressed and synthesized by human chondrocytes but not by synoviocytes, J. Clin. Invest., 97(9):2011-2019 (1996).
Schwartz et al.,Synthetic inhibitors of bacterial and mammalian interstitial collagenases, Prog. in Med. Chem., 29:271-334 (1992).

Affiliated with

Also associated with

Rating

Sulfamato hydroxamic acid metalloprotease inhibitor does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Sulfamato hydroxamic acid metalloprotease inhibitor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sulfamato hydroxamic acid metalloprotease inhibitor will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3670938